Minocycline hydrochloride
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03822 |
| CAS | 13614-98-7 |
| Molecular Weight | 493.94 |
| Molecular Formula | C23H27N3O7.HCl |
| Purity | Assay 96.0%-102.5% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-03822 | 5 g | $299 | In stock |
Online Inquiry
Add to cartDescription
Minocycline (INN) is a semi-synthetic broad-spectrum tetracycline antibiotic. Minocycline hydrochloride is the most lipid-soluble form, which binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis. In combination with CHIR 99021, (S)-(+)-Dimethindene maleate and human leukemia inhibitory factor, it induces the formation of extended pluripotent stem (EPS) cells.
Specification
| Related CAS | 10118-90-8 (free acid) |
| Synonyms | Minocycline HCl; Arestin; Minomycin |
| Storage | Preserve in tight containers, protected from light |
| IUPAC Name | (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;hydrochloride |
| Canonical SMILES | CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl |
| InChI | InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32);1H/t9-,11-,17-,23-;/m0./s1 |
| InChI Key | WTJXVDPDEQKTCV-VQAITOIOSA-N |
| Source | Semi-synthetic |
Properties
| Appearance | Yellow Crystalline Powder |
| Boiling Point | 659.4°C at 760 mmHg |
| Melting Point | 205-210°C (dec) |
| Solubility | Soluble in ethanol, methanol, DMF, DMSO |
Reference Reading
1. Treatment of Symptomatic Hepatic Cysts by Percutaneous Instillation of Minocycline Hydrochloride
NOBUO YAMADA, HARUHIDE SHINZAWA, Digestive Diseases and Sciences, Vol, 39, No. 11 (November 1994), pp, 2503-2509
Upon admission to the hospital for treatment, the patients were given 15 mg pentazocine and 25 mg hydroxyzine hydrochloride subcutaneously as premedication. After local analgesia of the puncture site with 1% mepivacaine hydro- chloride, a 15- or 20-cm-long, 21-gauge PTC needle (Hakko, Japan) was passed into the cyst under real-time ultrasonic guidance with a 3.5-MHz or 5-MHz convex transducer (model SSD-650, Aloka, Japan). In most cases, a radiograph of the cyst was obtained after injection of contrast medium to ensure that there was no communication with the biliary duct or extravasation into the peritoneal cavity. After aspiration of as much cystic fluid as possible, minocycline hydrochloride (Lederle, Japan) was injected into all cysts through the same puncture needle. Minocycline hydrochloride was dissolved in saline at a concentration of 200 mg to 9 ml and mixed with 1 ml of 2% mepivacaine hydrochloride to control pain. The pH of this mixture was about 2.4. The quantity of minocycline hydrochloride injected at any one time varied from 100 to 600 mg/cyst, depending on its size. In short, 100 mg of minocycline hydrochloride was injected into hepatic cysts smaller than 5 cm in diameter, 200-400 mg was instilled into cysts measuring 5-10 cm, and 600 mg was used for cysts larger than 10 cm in diameter. Thereafter we performed the aspiration and injection of remaining cystic fluid including minocycline hydrochloride several times using a 20-ml syringe so that the minocycline hydrochloride came into contact with all surfaces of the cystic cavity. In eight hepatic cysts of five patients, a small volume of cystic fluid containing minocycline hydrochloride was aspirated in order to measure the fluid pH, and this was compared with the pH of the cystic fluid before the injection of minocycline hydrochloride.
2. Percutaneous Injection Sclerotherapy with Minocycline Hydrochloride for Simple Renal Cysts
M. OHKAWA, S. TOKUNAGA, ORITO, M. SHIMAMURA, International Urology and Nephrology 25 (1), pp. 37-43 (1993)
No malignant cells were detected in the fluid of any patients, and the results of chemical analysis were similar to those previously reported. No cyst wall irregularities suggesting malignant tumour were found in any of the patients. Minor complications such as slight fever and pain were observed in 21 (12.8%) of the 164 minocycline-treated patients, while slight fever developed in 2 (10.0%) of the 20 control patients. Major complications such as haemorrhage and infection were not encountered in either group. Minocycline hydrochloride was detected in all serum and urine samples obtained after injection. The range of concentrations was wide, with the maximum value of 1.4 gg/ml in serum and 9.1 Bg/ml in urine (Table 2). Minocycline hydrochloride solutions ranged from pH 2.34 to pH 3.78, depending upon the volume of distilled water (pH 6.2) used as the diluent (Table 3).
3. Design of pH-Independent Extended Release Matrix Tablets of Minocycline Hydrochloride for the Treatment of Dementia
Kwang-Ho Cha, Junsung Park, Wonkyung Cho, Arch Pharm Res Vol 32, No 11, 1593-1598, 2009
Minocycline Hydrochloride is a broad-spectrum second generation semi-synthetic antibiotic belonging to the tetracycline family that is approved by the FDA (100-200 mg/day) for the treatment of acne vulgaris, some sexually transmitted diseases, and rheumatoid arthritis. Recently minocycline Hydrochloride was found to inhibit p38 MAPK activity, which contributes to apoptotic signal transduction and induces cell death, in animal models of Huntington’s disease (Chen et al., 2000), amyotrophic lateral sclerosis (Kim and Suh, 2009), Parkinson’s disease (Du et al., 2001), and other neurodegenerative diseases (Zuch et al., 2000; Barcia et al., 2003). As minocycline is effective for prevention and treatment of various dementias including Alzheimer’s disease and memory impairment (Dawson et al., 2003), our goal was to develop a pH-independent extended release matrix formulation for these applications.
Recommended Products
| BBF-03754 | Castanospermine | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
